ALTERNATING CHEMORADIOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL PLUS BLEOMYCIN BY CONTINUOUS INFUSION FOR LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE

被引:38
作者
AZLI, N
ARMAND, JP
RAHAL, M
WIBAULT, P
BOUSSEN, H
ESCHWEGE, F
SCHWAAB, G
GASMI, J
BACHOUCHI, M
CVITKOVIC, E
机构
[1] INST GUSTAVE ROUSSY, UNITE LA GRANGE VILLEJUIF, F-77176 VILLEJUIF, FRANCE
[2] INST SALAH AZAIZ, TUNIS, TUNISIA
[3] CTR ANTI CANC BENBADIS, CONSTANTINE, ALGERIA
关键词
D O I
10.1016/0959-8049(92)90005-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases. Protocol: two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilisations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 62 条
[1]   EXCELLENT RESPONSE TO CIS-PLATINUM BASED CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PREVIOUSLY UNTREATED ADVANCED NASOPHARYNGEAL CARCINOMA [J].
ALKOURAINY, K ;
CRISSMAN, J ;
ENSLEY, J ;
KISH, J ;
KELLY, J ;
ALSARRAF, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (04) :427-430
[2]   CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA - A RADIATION-THERAPY ONCOLOGY GROUP-STUDY [J].
ALSARRAF, M ;
PAJAK, TF ;
COOPER, JS ;
MOHIUDDIN, M ;
HERSKOVIC, A ;
AGER, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) :1342-1351
[3]  
ALSARRAF M, COMMUNICATION
[4]  
ANWAR M, 1986, J SURG ONCOL, V33, P194
[5]   ALTERNATING RADIOTHERAPY AND CHEMOTHERAPY SCHEDULES IN SMALL CELL LUNG-CANCER, LIMITED DISEASE [J].
ARRIAGADA, R ;
LECHEVALIER, T ;
BALDEYROU, P ;
PICO, JL ;
RUFFIE, P ;
MARTIN, M ;
ELBAKRY, HM ;
DUROUX, P ;
BIGNON, J ;
LENFANT, B ;
HAYAT, M ;
ROUESSE, JG ;
SANCHOGARNIER, H ;
TUBIANA, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (08) :1461-1467
[6]   HIGH COMPLETE RESPONSE IN ADVANCED NASOPHARYNGEAL CARCINOMA WITH BLEOMYCIN, EPIRUBICIN, AND CISPLATIN BEFORE RADIOTHERAPY [J].
BACHOUCHI, M ;
CVITKOVIC, E ;
AZLI, N ;
GASMI, J ;
CORTESFUNES, H ;
BOUSSEN, H ;
RAHAL, M ;
KALIFA, C ;
SCHWAAB, G ;
ESCHWEGE, F ;
WIBAULT, P ;
ARMAND, JP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07) :616-620
[7]  
BAKER SR, 1982, CANCER, V49, P163, DOI 10.1002/1097-0142(19820101)49:1<163::AID-CNCR2820490132>3.0.CO
[8]  
2-8
[9]   CHEMOTHERAPY OF METASTATIC AND OR RECURRENT UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA WITH CISPLATIN, BLEOMYCIN, AND FLUOROURACIL [J].
BOUSSEN, H ;
CVITKOVIC, E ;
WENDLING, JL ;
AZLI, N ;
BACHOUCHI, M ;
MAHJOUBI, R ;
KALIFA, C ;
WIBAULT, P ;
SCHWAAB, G ;
ARMAND, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1675-1681
[10]  
CHATANI M, 1986, CANCER, V57, P2267, DOI 10.1002/1097-0142(19860615)57:12<2267::AID-CNCR2820571205>3.0.CO